Glycogen synthase kinase-3 inhibitors

Details Glycogen synthase kinase-3 inhibitors Glycogen synthase kinase-3 inhibitors

2008-05-29

2010-11-16

Russel, Jeffrey E (Department: 1654)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

C530S327000, C530S328000, C530S345000

Reexamination Certificate

active

07833974

ABSTRACT:
Novel conjugates that are capable of inhibiting GSK-3 activity, a process of producing same, pharmaceutical compositions including same and methods of using same in the treatment of GSK-3 mediated conditions are disclosed. Methods of treating affective disorders using GSK-3 inhibitors are further disclosed.

REFERENCES:
patent: 1471621 (1923-10-01), McCord
patent: 2046068 (1936-06-01), Gray
patent: 3193159 (1965-07-01), Swindler
patent: 4186646 (1980-02-01), Martin
patent: 5462101 (1995-10-01), Mouchmouchian
patent: 5749925 (1998-05-01), Bocker et al.
patent: 5861266 (1999-01-01), Ullrich et al.
patent: 6057117 (2000-05-01), Harrison et al.
patent: 6153618 (2000-11-01), Schultz et al.
patent: 6326174 (2001-12-01), Joyce et al.
patent: 6441140 (2002-08-01), Comb et al.
patent: 6495376 (2002-12-01), Lu et al.
patent: 6780625 (2004-08-01), Eldar-Finkelman
patent: 6982318 (2006-01-01), Comb et al.
patent: 7157422 (2007-01-01), Eldar-Finkelman
patent: 7348308 (2008-03-01), Eldar
patent: 7378432 (2008-05-01), Eldar et al.
patent: 7446092 (2008-11-01), Eldar
patent: 2002/0147146 (2002-10-01), Eldar-Finkelman
patent: 2004/0162234 (2004-08-01), Eldar-Finkelman
patent: 2006/0069066 (2006-03-01), Eldar-Finkelman et al.
patent: 2006/0135408 (2006-06-01), Eldar-Finkelman
patent: 2007/0072791 (2007-03-01), Eldar-Finkelman
patent: 2007/0196883 (2007-08-01), Alessi et al.
patent: 2008/0312188 (2008-12-01), Eldar et al.
patent: 2009/0062180 (2009-03-01), Eldar
patent: 781806 (1957-08-01), None
patent: WO 95/01376 (1995-01-01), None
patent: WO 97/33601 (1997-09-01), None
patent: WO 97/41854 (1997-11-01), None
patent: WO 98/05961 (1998-02-01), None
patent: WO 98/16528 (1998-04-01), None
patent: WO 00/45237 (2000-08-01), None
patent: WO 00/59206 (2000-10-01), None
patent: WO 00/74663 (2000-12-01), None
patent: WO 01/49709 (2001-07-01), None
patent: WO 02/16318 (2002-02-01), None
patent: WO 02/24941 (2002-03-01), None
patent: WO 2004/052404 (2004-06-01), None
patent: WO 2004/052414 (2004-06-01), None
patent: WO 2005/000192 (2005-01-01), None
patent: WO 2006/054298 (2006-05-01), None
Chen et al. “The Mood-Stbilizing Agent Valproate Inhibits the Activity of Glycogen Synthase Kinase-3”, Journal of Neurochemistry, 72: 1327-1330, 1999.
Cheng et al. “‘Insulin-Like’ Effects of Lithium Ion on Isolated Rat Adipocytes. II. Specific Activation of Glycogen Synthase”, Molecular & Cellular Biochemistry, 56(2): 183-189, 1983. Abstract.
Coghlan et al. “Selective Small Molecule Inhibitors of Glycogen Synthase Kinase-3 Modulate Glycogen Metabolism and Gene Transcription”, Chemistry & Biology, 7: 793-803, 2000.
Cross et al. “The Inhibition of Glycogen Synthase Kinase-3 by Insulin or Insulin- Like Growth Factor 1 in the Rat Skeletal Muscle Cell Line L6 Is Blocked by Wortmannin, But Not by Rapamycin: Evidence That Wortmannin Blocks Activation of the Mitogen-Activated Protein Kinase Pathway in L6 Cells Between Ras and Raf”, Biochemical Journal, 303: 21-26, 1994.
Damiens et al. “Anti-Mitotic Properties of Indirubin-3′-Monoxime, A CDK/GSK-3 Inhibitor: Induction of Endoreplication Following Prophase Arrest”, Oncogene, 20: 3786-3797, 2001.
Davies et al. “Specificity and Mechanism of Action of Some Commonly Used Protein Kinase Inhibitors”, Biochemical Journal, 351: 95-105, 2000.
Eldar-Finkelman et al. “Glycogen Synthase Kinase 3: An Emerging Therapeutic Target”, Trends in Molecular Medicine, 8(3): 126-132, 2002.
Jicha et al. “A Confirmation- and Phosphorylation-Dependent Antibody Recognizing the Paired Helical Filaments of Alzheimer's Disease”, Journal of Neurochemistry, 69: 2087-2095, 1997.
Woodgett “Judging a Protein by More Than Its Name: GSK-3”, Science's STKE, 100(RE12): 1-11, 2001.
International Preliminary Examination Report Dated Sep. 6, 2005 From the International Preliminary Examining Authority Re.: Application No. PCT/IL03/01057.
Office Action Dated Dec. 12, 2008 From the State Intellectual Property Office of the People's Republic of China Re.: Application No. 200480024017.5.
Office Action Dated Oct. 22, 2008 From the Israeli Patent Office Re.: Application No. 172038.
Official Action Dated Feb. 8, 2008 From the US Patent and Trademark Office Re.: U.S. Appl. No. 10/538,171.
Official Action Dated Apr. 24, 2007 From the US Patent and Trademark Office Re.: U.S. Appl. No. 11/602,406.
Communication Pursuant to Article 94(3) EPC Dated Feb. 27, 2009 From the European Patent Office Re.: Application No. 05809234.7.
International Preliminary Report on Patentability Dated May 31, 2007 From the International Bureau of WIPO Re.: Application No. PCT/IL2005/001218.
Office Action Dated Dec. 17, 2008 From the Israeli Patent Office Re.: Application No. 168983 and Its Translation Into English.
Office Action Dated Oct. 22, 2008 From the Israeli Patent Office Re.: Application No. 172038.
Official Action Dated Aug. 2, 2007 From the US Patent and Trademark Office Re.: U.S. Appl. No. 11/280,209.
Official Action dated Feb. 18, 2009 From the US Patent and Trademark Office Re.: U.S. Appl. No. 12/149,336.
Official Action Dated Aug. 20, 2007 From the US Patent and Trademark Office Re.: U.S. Appl. No. 10/538,171.
Official Action Dated May 21, 2009 From the US Patent and Trademark Office Re.: U.S. Appl. No. 12/149,336.
Translation of the Office Action Dated Dec. 12, 2008 From the State Intellectual Property Office of the People's Republic of China Re.: Application No. 200480024017.5.
Kubinyi “Multiple Binding Modes”, Mattos et al., 3D QSAR in Drug Design. Theory Methods and Applications, Springer, 2-3: 243-244, 1998.
American Diabetes Association “Standards of Medical Care for Patients With Diabetes Mellitus”, Diabetes Care, 17(6): 616-623, 1994.
Barber et al. “Insulin Rescues Retinal Neurons From Apoptosis by a Phosphotidylinositol 3-Kinase/Akt-Mediated Mechanism That Reduces the Activation of Caspase-3”, The Journal of Biological Chemistry, 276(350): 32814-32821, 2001.
Barrett et al. “Proteinase Inhibitors”, Research Monographs in Cell and Tissue Physiology, V-XXII,1986.
Bijur et al. “Glycogen Synthase Kinese-3? Facilities Staurosporine- and Heat-Induced Apotosis”, The Journal of Biological Chemistry, 275(11): 7583-7590, 2000.
Burke et al. “4′-O[2(2-Fluoromalonyl)]-L-Tyrosine: A Phosphotyrosyl Mimic for the Preparation of Signal Transduction Inhabitory Peptides”, Journal of Medicinal Chemistry, 39: 1021-1027, 1996.
Burke et al. “Potent Inhibition of Insulin Receptor Dephosphorylation by a Hexamer Peptide Containing the Phosphotyrosyl Mimetic F2Pmp”, Biochemical and Biophysical Research Communications, 204(1): 129-134, 1994.
Burke et al. “Small Molecule Interactions With Protein-Tyrosine Phosphatase PTP 1B and Their Use in Inhibitor Design”, Biochemistry, 35: 15989-15996, 1996.
Chen et al. “Why Is Phosphonodifluoromethyl Phenylalanine a More Potent Inhibitory Moiety Than Phosphonomethyl Phenylalaline Towards Protein-Tyrosine Phosphatases?”, Biochemical and Biophysical Research Communications, 216(3):976-984, 1995.
Cheng et al. “‘Insulin-Like’ Effects of Lithium Ion on Isolated Rat Adipocytes L. Stimulation of Glycogenesis Beyond Glucose Transport”, Molecular and Cellular Biochemistry, 56: 177-182, 1983.
Chu et al. “Sequential Phosphorylation by Mitogen-Activated Protein Kinase and Glycogen Synthase Kinase 3 Represses Transcriptional Activation by Heat Shock Factor-1”, The Journal of Biological Chemistry, 271(48): 30847-30857, 1996.
Correll et al. “Inhibition of GSK3? Mediates Cell Survival in Differentiated PC-12 Cells Undergoing Apoptosis”, Society for Neuroscience, 25(2): 1519, 1999. Abstract No. 605.8.
Cross et al. “Selective Small-Molecule Inhibitors of Glycogen Synthase Kinase-3 Activity Protect Primary Neurons From Death”, Journal of Neurochemistry, 77: 94-102, 2001.
Cross et al. 

Affiliated with

Also associated with

Rating

Glycogen synthase kinase-3 inhibitors does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Glycogen synthase kinase-3 inhibitors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Glycogen synthase kinase-3 inhibitors will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4236673